JDD Spotlight: Guselkumab’s 5-Year Promise in Psoriasis
Curious about long-term breakthroughs in psoriasis care? A recent pooled analysis from the Phase 3 VOYAGE studies hints that guselkumab might be a game-changer, delivering robust, durable control for up to 5 years—even across diverse patient profiles.
What does this mean for your practice? Dive into the details behind these promising results and see how this could reshape your approach to managing moderate-to-severe psoriasis.
